Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0

作者：

Dholaria, Bhagirathbhai R.

Weisel, Katja

Mateos, Maria-Victoria

Goldschmidt, Hartmut

Martin, Thomas G.

Morillo, Daniel

Reece, Donna Ellen

Rodriguez-Otero, Paula

Bhutani, Manisha

D'Souza, Anita

Oriol, Albert

Rosinol, Laura

Bahlis, Nizar J.

Bakshi, Kalpana

Kang, Lijuan

Vandenberk, Lien

Smit, Marie-Anne Damiette

Wasch, Ralph

van de Donk, Niels W. C. J.

Chari, Ajai

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany

[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA

[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[16] Janssen Res & Dev, Spring House, PA USA

[17] Janssen Res & Dev, Antwerp, Belgium

[18] Janssen Biol Europe, Leiden, Netherlands

[19] Freiburg Univ, Med Ctr, Freiburg, Germany

[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[21] Mt Sinai Sch Med, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8003

引用

页数：1

共 50 条

[21] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Chari, Ajai
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Rodriguez-Otero, Paula
Pineiro, Luis
Jakubowiak, Andrzej
de Boer, Carla
Wang, Jianping
Clemens, Pamela L.
Ukropec, Jon
Schecter, Jordan
Lonial, Sagar
Moreau, Philippe
BLOOD, 2019, 134 (05) : 421 - 431
[22] Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
Lakshman, Arjun
Abeykoon, Jithma P.
Kumar, Shaji
Rajkumar, S. Vincent
Kourelis, Taxiarchis
Buadi, Francis
Dingli, David
Lacy, Martha
Gonsalves, Wilson I.
Dispenzieri, Angela
Kyle, Robert A.
Lin, Yi
Go, Ronald S.
Warsame, Rahma M.
Hayman, Suzanne R.
Russell, Stephen
Leung, Nelson
Gertz, Morie A.
Kapoor, Prashant
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).
Shank, Brandon R.
Primeaux, Brian
Horowitz, Sandra B.
Yeung, Erin K.
Lee, Irene Y.
Kaufman, Gregory Peter
Lee, Hans Chulhee
Manasanch, Elisabet Esteve
Patel, Krina K.
Orlowski, Robert Z.
Weber, Donna M.
Thomas, Sheeba K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA
Usmani, Saad
Mateos, Maria-Victoria
Hungria, Vania
Iida, Shinsuke
Bahlis, Nizar J.
Nahi, Hareth
Magen, Hila
Cavo, Michele
Hulin, Cyrille
White, Darrell
De Stefano, Valerio
Slavcev, Mary
Heuck, Christoph
Qin, Xiang
Masterson, Tara
Lantz, Kristen
Gries, Katharine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E247 - E248
[25] HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
Richardson, Paul G.
Oriol, Albert
Larocca, Alessandra
Rodriguez Otero, Paula
Norkin, Maxim
Blade, Joan
Cavo, Michele
Hassoun, Hani
Leleu, Xavier
Alegre, Adrian
Maisel, Christopher
Paner, Agne
Mazumder, Amitabha
Zonder, Jeffrey A.
Puig, Noemi
Harran, John
Harmenberg, Johan
Thuresson, Sara
Zubair, Hanan
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S329 - S330
[26] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
Tungesvik, Alexandre
Huang, Jessica
Sudalagunta, Praneeth
Dimaggio, Elizabeth
De Avila, Gabe
Tandon, Ankita
Nelson, Rebeccah
Olson, Laura
Tobon, Katherine
Shain, Kenneth
Brayer, Jason
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
[27] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Cohen, Yael
Morillo, Daniel
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle
Beelen, Melissa
Vanak, Jill
Banerjee, Arnob
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
[28] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
Schinke, C.
Touzeau, C.
Minnema, M. C.
van de Donk, N. W.
Rodriguez-Otero, P.
Mateos, M. -V.
Rasche, L.
Ye, J. C.
Vishwamitra, D.
Ma, X.
Qin, X.
Campagna, M.
Masterson, T.
Hilder, B.
Tolbert, J.
Renaud, T.
Goldberg, J.
Heuck, C.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
[29] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
Mateos, Maria-Victoria
Blade, Joan
Larocca, Alessandra
Oriol, Albert
Rodriguez, Paula
Alegre, Adrian
Cavo, Michele
Moreb, Jan S.
Paner, Agne
Gabrail, Nashat
Halka, Kathleen G.
Hassoun, Hani
Maisel, Christopher
Mazumder, Amitabha
Zonder, Jeffrey A.
Ocio, Enrique M.
Byrne, Catriona
Harmenberg, Johan
Thuresson, Sara
Nordstrom, Eva
Lindberg, Jakob
Richardson, Paul G.
BLOOD, 2017, 130
[30] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
Chari, Ajai
Usmani, Saad Zafar
Mateos, Maria-Victoria
Van De Donk, Niels
Kaufman, Jonathan L.
Moreau, Philippe
Rocafiguera, Albert Oriol
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Farnsworth, Andrew
Nahi, Hareth
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →